Drought tolerance gene identified in wheat
15 July, 2005 by Graeme O'NeillIn the nick of time, climatically speaking, an Australian National University research team has cloned a plant gene that could markedly increase water-use efficiency in major food crops, including cereals.
Stem Cell Sciences raises £6 million on AIM
14 July, 2005 by Ruth BeranDespite terrorist attacks in London last week, BioTech Capital (ASX:BTC) investee company Stem Cell Sciences has raised £6 million (approximately AUD$14 million) as part of its initial public offering and listing on London's Alternative Investment Market (AIM).
Parasite network aims to focus research efforts
12 July, 2005 by Helen SchullerA new, federally-funded Research Network for Parasitology met for the first time in Melbourne last week, bringing together more than 200 researchers in a bid to focus research efforts in the area.
AVT Plasma calls in liquidator after China about-face
06 July, 2005 by Ruth BeranAVT Plasma (ASX:AVT) has suspended trading in its shares, following a board decision to wind up the company and appoint a provisional liquidator.
Stem cell review committee meets in Sydney
05 July, 2005 by Graeme O'NeillThe independent committee appointed to review federal laws restricting stem cell research in Australia met for the first time yesterday, in Sydney.
Why biotech is hot in India
01 July, 2005 by Russell McInnesAfter a recent first-hand look, Russell McInnes shares some perspectives on India's burgeoning biotech industry.
AVT Plasma sets its sights on China
30 June, 2005 by Ruth BeranProducing products from human blood plasma is a lucrative business and the Chinese market provides a significant long-term opportunity, AVT Plasma's CEO tells Ruth Beran.
Stem Cell Sciences moves to list on AIM
24 June, 2005 by Ruth BeranBiotech Capital (ASX:BTC) investee company Stem Cell Sciences is looking to raise up to £10 million on London's Alternative Investment Market (AIM).
Researchers make oocytes from embryonic stem cells
23 June, 2005 by Graeme O'NeillMonash University fertility researchers have succeeded in producing oocytes -- eggs -- from mouse embryonic stem (ES) cells, offering hope to couples who are unable to conceive, even by in vitro fertilisation, because the partner lacks viable eggs.
Agenix's Thromboview found safe
20 June, 2005 by Ruth BeranBrisbane Agenix (ASX:AGX, OTC(NASDAQ):AGXLY) has found that its Thromboview blood clot diagnostic is safe and not associated with an immune response, according to results from its Phase Ib deep vein thrombosis (DVT) study.
GroPep releases infertility data
14 June, 2005 by Ruth BeranKey pre-clinical data on GroPep's (ASX:GRO) infertility drug, PV903, showing a halving of the miscarriage rate in a strain of female mice susceptible to the immune rejection of the foetus, will be presented at a reproductive immunology meeting this week in the US.
Avantogen to co-develop genital herpes vaccine
08 June, 2005 by Ruth BeranAvantogen (ASX:ACU), formerly known as Australian Cancer Tehcnology, is to team up with the University of Alabama at Birmingham (UAB) to conduct a preclinical study to develop a new therapeutic vaccine for herpes simplex virus type 2 (HSV-2).
How microbial screening is uncovering buried treasure
03 June, 2005 by Graeme O'NeillGenome scientist Craig Venter is cruising the world in his yacht, sampling the genetic diversity of marine bacteria and microbes wafted over the oceans by intercontinental winds, and finding enough genetic treasure to keep drug-hunters in work for a few centuries.
TGA approves VacTX vaccine trials
26 May, 2005 by Graeme O'NeillAustralia's Therapeutic Goods Administration (TGA) has approved a clinical trial of a new immunotherapeutic vaccine for chronic hepatitis C infection, developed by VacTX, a joint venture between EqiTX (ASX:EQX) and the CRC for Vaccine Technology
Living Cell Technologies finalises technology acquisition
19 May, 2005 by Graeme O'NeillAuckland-based cell therapy company Living Cell Technologies (ASX:LCT) will hold a general meeting next week to formally seal a deal under which it has acquired technology and IP worth US$90 million from with US cell-therapy company Theracyte.
